Phenotypic differences between apolipoprotein e genetic subgroups: Research and clinical implications

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

With the recent interest in Alzheimer's disease course modification and earlier, even preclinical, intervention, questions have arisen regarding the potentially confounding impact of apolipoprotein E (APOE) genotype on study design, therapeutic outcomes, and even clinical practice. APOE e4 carriers have a faster rate of cognitive decline both preclinically and during the mild cognitive impairment (MCI) stage, and a higher burden of cerebrovascular amyloid that may be the basis for the observed gene-dose-related increased frequency of immunomodulatory therapy-induced meningoencephalitis and cerebral microhemorrhages. To date, this has impacted study design in some research trials but not clinical practice.

Original languageEnglish (US)
Article number20
JournalAlzheimer's Research and Therapy
Volume4
Issue number3
DOIs
StatePublished - 2012

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Fingerprint Dive into the research topics of 'Phenotypic differences between apolipoprotein e genetic subgroups: Research and clinical implications'. Together they form a unique fingerprint.

  • Cite this